Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: Identification of specific tumor marker and potential targets for immunotherapy

Cancer Biology and Therapy

Volumn 12, Issue 3, 2011, Pages 191-197

  Forghanifard, Mohammad Mahdi ^a,b   Gholamin, Mehran ^b   Farshchian, Moein ^b   Moaven, Omeed ^b,c   Memar, Bahram ^d   Forghani, Mohammad Naser ^d   Dadkhah, Ezzat ^b   Naseh, Hossein ^d   Moghbeli, Meysam ^b   Raeisossadati, Reza ^b   Abbaszadegan, Mohammad Reza ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer testis antigens; Cancer vaccine; Esophageal squamous cell carcinoma; Real time PCR; Tumor marker

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER VACCINE; IMMUNOMODULATING AGENT; MELANOMA ANTIGEN 4; NUCLEASE; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASSAY; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; GENE EXPRESSION PROFILING; GENE INTERACTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LAGENIDIUM; LYMPH NODE METASTASIS; MALE; PATHOLOGY; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TESTIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79961244055     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.3.15949     Document Type: Article

References (52)

1. Gholamin M, Moaven O, Memar B, Farshchian M, Naseh H, Malekzadeh R, et al. Overexpression and interactions of interleukin-10, transforming growth factorbeta and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J Surg 2009; 33:1439-45.
2. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2009; 20:556-63.
3. Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for cancer vaccine development. J Biomed Biotechnol 2010; In press.
4. Kalejs M, Erenpreisa J. Cancer/testis antigens and gametogenesis: a review and "brain-storming" session. Cancer Cell Int 2005; 5:4.
5. Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B. Cancer/testis antigen expression in human mesenchymal stem cells: downregulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 2005; 65:2207-15. (Pubitemid 40490129)
6. Costa FF, Le Blanc K, Brodin B. Concise review: cancer/testis antigens, stem cells and cancer. Stem Cells 2007; 25:707-11. (Pubitemid 46354230)
7. Bandic D, Juretic A, Sarcevic B, Separovic V, Kujundzic-Tiljak M, Hudolin T, et al. Expression and possible prognostic role of MAGE-A4, NY-ESO-1 and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat Med J 2006; 47:32-41. (Pubitemid 43326900)
8. Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7 and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 2003; 3:9.
9. Hudolin T, Kastelan Z, Derezic D, Basic-Jukic N, Cesare Spagnoli G, Juretic A, et al. Expression of MAGE-A1, MAGE-A3/4 and NY-ESO-1 cancer-testis antigens in fetal testis. Acta Dermatovenerol Croat 2009; 17:103-7.
10. Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 2006; 28:1089-98.
11. Taniura H, Kobayashi M, Yoshikawa K. Functional domains of necdin for protein-protein interaction, nuclear matrix targeting and cell growth suppression. J Cell Biochem 2005; 94:804-15. (Pubitemid 41420277)
12. Bai S, He B, Wilson EM. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol Cell Biol 2005; 25:1238-57. (Pubitemid 40204904)
13. Sakurai T, Itoh K, Higashitsuji H, Nagao T, Nonoguchi K, Chiba T, et al. A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. J Biol Chem 2004; 279:15505-14. (Pubitemid 38618951)
14. Laduron S, Deplus R, Zhou S, Kholmanskikh O, Godelaine D, De Smet C, et al. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res 2004; 32:4340-50. (Pubitemid 39232306)
15. Peikert T, Specks U, Farver C, Erzurum SC, Comhair SA. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res 2006; 66:4693-700.
16. Nagao T, Higashitsuji H, Nonoguchi K, Sakurai T, Dawson S, Mayer RJ, et al. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem 2003; 278:10668-74. (Pubitemid 36800336)
17. Dawson S, Higashitsuji H, Wilkinson AJ, Fujita J, Mayer RJ. Gankyrin: a new oncoprotein and regulator of pRb and p53. Trends Cell Biol 2006; 16:229-33. (Pubitemid 43728872)
18. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100:2014-21.
19. Almeida LG, Sakabe NJ, de Oliveira AR, Silva MC, Mundstein AS, Cohen T, et al. CTdatabase: a knowledge- base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 2009; 37:816-9.
20. Grah J, Samija M, Juretic A, Sarcevic B, Sobat H. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features. Coll Antropol 2008; 32:731-6.
21. Akcakanat A, Kanda T, Tanabe T, Komukai S, Yajima K, Nakagawa S, et al. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy. Int J Cancer 2006; 118:123-8. (Pubitemid 41681588)
22. Fujita S, Wada H, Jungbluth AA, Sato S, Nakata T, Noguchi Y, et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res 2004; 10:6551-8. (Pubitemid 39346550)
23. Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura E, Yoshida Y, et al. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol 2004; 54:95-100. (Pubitemid 38858372)
24. Peng LP, Liu HY, Ran YL, Sun LX, Yu L, Yang ZH. [Expression of NY-ESO-1 gene in human esophageal carcinoma and its cloning]. Ai Zheng 2002; 21:469-72.
25. Liang Z, Sun ZY, Yuan YH, Han Y, Wang Y, Gu J, et al. [The expression of 11 cancer/testis (CT) antigen genes in esophageal carcinoma]. Zhonghua Zhong Liu Za Zhi 2005; 27:534-7.
26. Zambon A, Mandruzzato S, Parenti A, Macino B, Dalerba P, Ruol A, et al. MAGE, BAGE and GAGE gene expression in patients with esophageal squamous cell carcinoma and adenocarcinoma of the gastric cardia. Cancer 2001; 91:1882-8. (Pubitemid 32424115)
27. Quillien V, Raoul JL, Heresbach D, Collet B, Toujas L, Brasseur F. Expression of MAGE genes in esophageal squamous-cell carcinoma. Anticancer Res 1997; 17:387-91. (Pubitemid 27116697)
28. Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L, et al. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer 2009; 125:1365-71.
29. Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, et al. Prognostic impact of cancer/ testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 2008; 8:2.
30. Bellati F, Napoletano C, Tarquini E, Palaia I, Landi R, Manci N, et al. Cancer testis antigen expression in primary and recurrent vulvar cancer: association with prognostic factors. Eur J Cancer 2007; 43:2621-7. (Pubitemid 350086939)
31. Hudolin T, Juretic A, Pasini J, Tomas D, Spagnoli GC, Heberer M, et al. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4 and NY-ESO-1 in squamous cell carcinoma of the penis. Urology 2006; 68:205-7. (Pubitemid 44037716)
32. Hudolin T, Juretic A, Spagnoli GC, Pasini J, Bandic D, Heberer M, et al. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4 and NY-ESO-1 in cancerous and benign prostatic tissue. Prostate 2006; 66:13-8. (Pubitemid 43005945)
33. Sarcevic B, Spagnoli GC, Terracciano L, Schultz-Thater E, Heberer M, Gamulin M, et al. Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma. Oncology 2003; 64:443-9. (Pubitemid 36682960)
34. Jungbluth AA, Stockert E, Chen YT, Kolb D, Iversen K, Coplan K, et al. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer 2000; 83:493-7. (Pubitemid 30487863)
35. Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson J, et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 1999; 59:241-8. (Pubitemid 29062984)
36. Yamanaka K, Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S. Expression of MAGE genes in renal cell carcinoma. Int J Mol Med 1998; 2:57-60.
37. Toh Y, Yamana H, Shichijo S, Fujita H, Tou U, Sakaguchi M, et al. Expression of MAGE-1 gene by esophageal carcinomas. Jpn J Cancer Res 1995; 86:714-7.
38. Patard JJ, Brasseur F, Gil-Diez S, Radvanyi F, Marchand M, Francois P, et al. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer 1995; 64:60-4.
39. Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995; 63:375-80.
40. Cuffel C, Rivals JP, Zaugg Y, Salvi S, Seelentag W, Speiser DE, et al. Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer; 128:2625-34.
41. Yanagawa N, Tamura G, Oizumi H, Endoh M, Motoyama T. MAGE expressions mediated by demethylation of MAGE promoters induce progression of non-small cell lung cancer. Anticancer Res 31:171-5.
42. Perez D, Hauswirth F, Jager D, Metzger U, Samartzis EP, Went P, et al. Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors. Int J Cancer; 128:2947-52.
43. Bai S, Wilson EM. Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Mol Cell Biol 2008; 28:1947-63. (Pubitemid 351342626)
44. Xiao J, Chen HS. Biological functions of melanoma-associated antigens. World J Gastroenterol 2004; 10:1849-53. (Pubitemid 39029277)
45. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 2006; 103:11160-5. (Pubitemid 44156489)
46. Marcar L, Maclaine NJ, Hupp TR, Meek DW. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res 70:10362-70.
47. Mahajan A, Guo Y, Yuan C, Weghorst CM, Tsai MD, Li J. Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16. J Mol Biol 2007; 373:990-1005. (Pubitemid 47505248)
48. INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma. BMC Cancer 10:138.
49. Lethe B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A, et al. LAGE-1, a new gene with tumor specificity. Int J Cancer 1998; 76:903-8. (Pubitemid 28262112)
50. Glazer CA, Smith IM, Ochs MF, Begum S, Westra W, Chang SS, et al. Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PLoS One 2009; 4:8189.
51. Akers SN, Odunsi K, Karpf AR. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol 6:717-32.
52. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11:8055-62. (Pubitemid 41698748)